Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-768-7 | CAS number: 7723-14-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
LD50, Oral, Rats > 2000 mg/kg bodyweight.
LD50 (4 hours), Inhaled, Rats > 5.75 mg/L.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
An acute oral toxicity study in rats was conducted (Huntingdon Life Sciences, 2010) to determine the acute LD50 of Fe3P when administered orally. The study was conducted according to EC test guideline B1, OECD guideline 423, and US EPA and Japanese test guidelines, and in compliance with GLP.
Two groups of three fasted female rats received a single oral gavage dose at 300 mg/kg bodyweight; as the results at this level indicated that the LD50 was greater than 300 mg/kg bodyweight, a further two groups of three fasted females received a single oral gavage dose of 2000 mg/kg bodyweight.
There were no deaths during the study. The only clinical sign of a reaction to treatment noted during the observation period was abnormally coloured faeces (black) seen in all animals dosed at 300 mg/kg, and three females dosed at 2000 mg/kg; these signs had resolved by day 2 of observation. A low bodyweight gain was observed late in the observation period for two animals at 300 mg/kg and three animals dosed at 2000 mg/kg. No abnormalities were noted in any animal during the macroscopic examination at study termination.
The acute median lethal oral dose to rate was demonstrated to be greater than 2000 mg/kg bodyweight.
An acute inhalation toxicity study in rats was conducted (Huntingdon Life Sciences, 2011) to determine the acute LD50 of Fe3P by inhalation exposure. The study was conducted according to EC test guideline B2, OECD test guideline 403, and US EPA and Japanese test guidelines, and was performed in compliance with GLP.
1 control group and 1 test group each consisting of 5 male and 5 female Sprague Dawley rats were administered a single 4 -hour snout-only exposure, then observed over 14 days prior to sacrifice and macropathological examination. The time-weighted average aerosol concentration of Fe3P in the treated group was 5.75 mg/L, which was close to the target concentration of 5 mg/L. Individual and mean calculated Mass median aerodynamic diameter (MMAD) values were above the optimal range of 1 - 4 µm; the average MMAD was 8 µm.
There were no unscheduled deaths during the study. Clinical signs were limited to grey staining of the head in all animals of the treated group, and the forepaws in the majority of animals in the treatment group. This was no longer evident at the first check during the observation period. There were no treatment related effects on bodyweight. Macroscopic pathological examination following sacrifice revealed a dark brown colour in the lungs of treated animals, a higher relative weight of lungs in the treated group by comparison to the control group, and enlarged tracheobronchial lymph nodes seen in treated animals.
The LC50 (4 hour) in rats of Fe3P was found to be greater than 5.75 mg/L under the conditions applied during this test.
Justification for classification or non-classification
The oral LD50 in rats of Fe3P was determined to be greater than 2000 mg/kg bodyweight. According to both the Classification Labelling and Packaging Regulation (CLP, EC number 1272/2008) and the Dangerous Substances Directive (DSD, Directive 67/548/EEC), classification for acute oral toxicity only applies where the oral LD50in rats is equal to or less than 2000 mg/kg bodyweight; on this basis Fe3P does not require classification for acute oral toxicity.
The inhaled LC50in rats of Fe3P was determined to be greater than 5 mg/L. According to both the CLP Regulation and the DSD as above, classification for acute oral toxicity only applies where the inhaled LC50in rats is equal to or less than 5 mg/L; on this basis Fe3P does not require classification for acute inhaled toxicity.
Although the studies noted above were designed to determine the lethal dose / concentration of Fe3P, and signs of sublethal toxicity were not observed in detail, the macroscopic pathology in each case did not indicate Specific Target Organ Toxicity (STOT, single exposure) by either administration route. The differences between the lungs of the treated group animals and the control group animals seen in the acute inhalation study (Huntingdon Life Sciences, 2011) were expected, and relate to the presence of test material in the lungs of the treated animals (increased lung weights and dark brown colour in the lungs) and the elimination response (enlarged tracheobronchial lymph nodes); these observations are not indicators of substance-specific toxicity.
On this basis, Fe3P does not require classification for STOT following single exposure by either the oral or inhaled exposure routes. Despite that no data are available for dermal exposure, classification of Fe3P for single-exposure STOT via this route is also not anticipated in view of its chemical inertness and its poor water solubility.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.